Charles W. Ashley

Charles W. Ashley

Auto-generated profile, based on publicly available information

Charles W. Ashley

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2009 in Blood
Verified
Journal Article
Open access
PDF file
GBGaëlle Beriou
Gaëlle Beriou
CCCristina M. Costantino
Cristina M. Costantino
CACharles W. Ashley
Charles W. Ashley
LYLi Yang
Li Yang
VKVijay K. Kuchroo
Vijay K. Kuchroo
DHDavid A. Hafler
David A. Hafler
Although implicated in antagonistic functions, both regulatory T cells (Tregs) and Th17 effector cells play an important role in controlling autoimmune pathogenesis. Paradoxically, recent studies indicate that Tregs have the capacity to produce interleukin-17 (IL-17), although the ability of these cells to retain their suppressive function remains unknown. Here we report that human Tregs within the CD4+CD45RA−CD25highCCR6+HLA-DR−FoxP3+ population produce IL-17 when activated in the presence of the proinflammatory cytokines IL-1β and IL-6, whereas IL-17 secretion was inhibited by TGFβ. To assess the ability of a single Treg to secrete IL-17 and to suppress in vitro immune function, we isolated clones from this population. We found that IL-17+/FoxP3+ Treg clones retain suppressive function and exhibit the plasticity to secrete IL-17 or suppress depending on the nature of the stimulus provided. IL-17 production by these Treg clones was accompanied by sustained FoxP3 expression and concomitant, but reversible, loss of suppressive activity. Our data demonstrate that at the single cell level a subset of in vitro suppressive FoxP3+ cells can be driven to secrete IL-17 under inflammatory conditions. These findings suggest a new mechanism by which inflammation can drive Tregs to secrete IL-17, thereby dampening suppression and promoting an inflammatory milieu.

22 January 2015 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
QJQiaoying Jiang
Qiaoying Jiang
LYLiwei Yang
Liwei Yang
CACharles Ashley
Charles Ashley
EMErin E Medlin
Erin E Medlin
DKDavid M Kushner
David M Kushner
ZYzheng yanmei
zheng yanmei
Uterine rupture classically presents with severe abdominal pain, loss of fetal station, vaginal bleeding, and shock. We present a case of uterine rupture presenting as significant urinary retention that occurred following a second trimester abortion induced with mifepristone and misoprostol. Uterine rupture was discovered unexpectedly on diagnostic laparoscopy. The uterine rupture was contained by dense adhesions between the omentum and bladder with the previous uterine cesarean hysterotomy scar. This case highlights the difficulties in diagnosis of abnormal placentation and an unusual presentation of uterine rupture. This case was managed successfully laparoscopically.

31 March 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PJPhilip L. De Jager
Philip L. De Jager
CBClare M. Baecher-Allan
Clare M. Baecher-Allan
LMLisa M. Maier
Lisa M. Maier
AAAriel T. Arthur
Ariel T. Arthur
LOLinda Ottoboni
Linda Ottoboni
DHDavid A. Hafler
David A. Hafler
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system associated with demyelination and axonal loss. A whole genome association scan suggested that allelic variants in the CD58 gene region, encoding the costimulatory molecule LFA-3, are associated with risk of developing MS. We now report additional genetic evidence, as well as resequencing and fine mapping of the CD58 locus in patients with MS and control subjects. These efforts identify a CD58 variant that provides further evidence of association with MS ( P = 1.1 × 10 −6 , OR 0.82) and the single protective effect within the CD58 locus is captured by the rs2300747 G allele. This protective rs2300747 G allele is associated with a dose-dependent increase in CD58 mRNA expression in lymphoblastic cell lines ( P = 1.1 × 10 −10 ) and in peripheral blood mononuclear cells from MS subjects ( P = 0.0037). This protective effect of enhanced CD58 expression on circulating mononuclear cells in patients with MS is supported by finding that CD58 mRNA expression is higher in MS subjects during clinical remission. Functional investigations suggest a potential mechanism whereby increases in CD58 expression, mediated by the protective allele, up-regulate the expression of transcription factor FoxP3 through engagement of the CD58 receptor, CD2, leading to the enhanced function of CD4 + CD25 high regulatory T cells that are defective in subjects with MS.

25 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CACharles W. Ashley
Charles W. Ashley
PSPier Selenica
Pier Selenica
JPJuber Patel
Juber Patel
MWMichelle Wu
Michelle Wu
JNJosip Nincevic
Josip Nincevic
BWBritta Weigelt
Britta Weigelt
Purpose: We sought to determine whether sequencing analysis of circulating cell-free DNA (cfDNA) in patients with prospectively accrued endometrial cancer captures the mutational repertoire of the primary lesion and allows for disease monitoring. Experimental Design: Peripheral blood was prospectively collected from 44 newly diagnosed patients with endometrial cancer over a 24-month period (i.e., baseline, postsurgery, every 6 months after). DNA from the primary endometrial cancers was subjected to targeted next-generation sequencing (NGS) of 468 cancer-related genes, and cfDNA to a high-depth NGS assay of 129 genes with molecular barcoding. Sequencing data were analyzed using validated bioinformatics methods. Results: cfDNA levels correlated with surgical stage in endometrial cancers, with higher levels of cfDNA being present in advanced-stage disease. Mutations in cfDNA at baseline were detected preoperatively in 8 of 36 (22%) patients with sequencing data, all of whom were diagnosed with advanced-stage disease, high tumor volume, and/or aggressive histologic type. Of the 38 somatic mutations identified in the primary tumors also present in the cfDNA assay, 35 (92%) and 38 (100%) were detected at baseline and follow-up, respectively. In 6 patients with recurrent disease, changes in circulating tumor DNA (ctDNA) fraction/variant allele fractions in cfDNA during follow-up closely mirrored disease progression and therapy response, with a lead time over clinically detected recurrence in two cases. The presence of ctDNA at baseline (P < 0.001) or postsurgery (P = 0.014) was significantly associated with reduced progression-free survival. Conclusions: cfDNA sequencing analysis in patients with endometrial cancer at diagnosis has prognostic value, and serial postsurgery cfDNA analysis enables disease and treatment response monitoring. See related commentary by Grant et al., p. 305

15 October 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CACharles W. Ashley
Charles W. Ashley
CBClare M. Baecher-Allan
Clare M. Baecher-Allan
MHC class II expression identifies an effector subset of human CD4+CD25highFoxP3high natural regulatory T cells (DR+ Tregs) that induces more rapid suppression and exhibits higher FoxP3 expression than the remaining Treg population. Although Tregs are known to be highly sensitive to apoptosis, in this study we demonstrate that this sensitivity is primarily a feature of DR+ Tregs. Granzyme B (GzmB) is strongly expressed by nonregulatory responder CD4 T cells, whereas effector DR+ Tregs express little GzmB. Strong TCR stimulation markedly increases the expression of GzmB in all dividing responder CD4 T cells and mitigates the suppression by DR+ Tregs. DR+ Treg suppressive activity reemerges if GzmB is neutralized. We show that responder cells actively kill effector Tregs by producing GzmB in response to strong TCR stimulation. Thus, the production of GzmB by strongly activated CD4 T cells represents a mechanism by which CD4 T cells resist Treg suppression.

1 March 2007 in Tetrahedron Letters
Verified
Journal Article
Closed access
BLBrian R. Linton
Brian R. Linton
MRMichael H. Reutershan
Michael H. Reutershan
CAChristopher M. Aderman
Christopher M. Aderman
ERElizabeth A. Richardson
Elizabeth A. Richardson
KBKristen R. Brownell
Kristen R. Brownell
SMScott J. Miller
Scott J. Miller